Published 11 years ago.
About a 4 minute read.
Press Release Monday, April 30, 2012 - 9:00am (3BL Media) April 30, 2012 - When it comes to health care products, environmental sustainability and green attributes rank high in the purchasing decisions of Institutional Delivery Networks (IDNs) and hospitals in the United States, Brazil, Germany, and Italy, new research reveals. In fact, a majority of respondents (54%) rated the impact of “green” on purchasing decisions for health care products and supplies—specifically, pharmaceuticals and medical devices and diagnostics—an 8 or higher on a 10-point scale. “Such a high rating means they are emotionally attached, that they feel strongly about it,” explains Dave Bauer, Senior Market Research Consultant, of SK&A, an independent research firm based in Irvine, Calif., that conducted the research on behalf of Medical Devices & Diagnostics Global Services LLC, a Johnson & Johnson Company. In January through March 2012, SK&A surveyed key decision makers within IDNs and hospitals on the importance of green/sustainability on their purchasing decisions. Respondents included health care professionals, procurement/materials management, and hospital executives in all four countries. The completed surveys (145 in the United States., 50 in Germany, 50 in Italy, and 62 in Brazil) were then compiled and averaged on a non-weighted basis to calculate the global results. The survey found that nearly one-third of current requests for proposals for medical products include green attributes, while key decision makers expect nearly 40% of future requests for proposals to include green attributes. The report also found that among customer perceptions of top manufacturers about their level of green sustainability, Johnson & Johnson is the highest rated company globally with 45% of respondents rating them an 8 or higher. “The research underscores our Credo commitment to protecting the environment and natural resources,” said Keith Sutter, Senior Product Director, Worldwide Environment, Health & Safety. “Our customers expect us to provide them with environmentally-preferable product offerings that align with their values,” Sutter said. “Our Earthwards® process is the way we at Johnson & Johnson address these customer demands for more sustainable and innovative healthcare products.” The proprietary Earthwards® process enables Johnson & Johnson company brands to develop and market greener products through lifecycle analysis. Every Earthwards® recognized product must achieve a greater than 10 percent improvement in at least three of the seven goal areas: materials used, packaging reduction, energy reduction, waste reduction, water reduction, positive social impact or benefit, and product innovation. To learn more about the Earthwards® process, please visit www.earthwards.com. These topics and more will be discussed at the Greener Product Innovation & Solutions for Healthcare Facilities Session at CleanMed 2012 in Denver Colorado April 30 – May 2. Be sure to attend the session, from 2:30 - 4:00 pm on Tuesday May 1st featuring Al Iannuzzi from Johnson & Johnson and David Spitzley from Kimberly Clark where the Johnson & Johnson Earthwards® process and Kimberly Clark’s EcoLogical will be presented and case studies will be discussed. Follow the discussion from CleanMed on Twitter: @jnjstories, @jnjcomm, #CleanMed ABOUT JOHNSON & JOHNSON Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. Resources (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.) Contact Keith Sutter +1 (267) 207-9724 Johnson & Johnson
Published May 7, 2012 8am EDT / 5am PDT / 1pm BST / 2pm CEST